

1
A⁸
cont.
corticosteroid include the proprietary formulations Betnovate RD™ (bethamethasone valerate, ready diluted), Aureocort™ (triamcinolone acetonide and chlortetracycline hydrochloride (an antibiotic)), and Eumovate™ (clobetasone butyrate). A 1% hydrocortisone preparation may also be used.

Page 27, line 29:

A⁸ sorbitan tristearate or Polawax NF™ 2.0%

Page 29, line 25:

A⁹ Polawax NF™ 2.0%

Page 30, line 2:

A¹⁰ Miranol™ 2.0%

Page 30, line 3:

A¹¹ Procetyl AWS™

In the Claims

✓
Please cancel Claims 2, 6-8, 14, 16, 18-19, and 24-27.

✓
Please amend Claims 1, 3-5, 9-10, 12-13, 15, 17, 20-23, 28 and 29 as follows.

A¹²
but B¹⁷
1. A composition comprising an amphoteric surfactant, an alkoxyated cetyl alcohol and a polar drug selected from the group consisting of sodium cromoglycate and nedocromil sodium.

A¹³
3. A composition according to Claim 1 wherein the amphoteric surfactant is a balanced amphoteric surfactant.

Sub 2
A¹³

4. A composition according to Claim 1 wherein the alkoxyated cetyl alcohol is polypropoxyated cetyl alcohol.

5. A composition according to Claim 1 wherein the amphoteric surfactant comprises disodium cocoamphodiacetate.

A¹⁴

9. A composition according to Claim 1 wherein the composition further comprises a corticosteroid.

10. A composition according to Claim 1 wherein the composition comprises an aqueous phase and an oil phase.

? does not further limit

12. A composition according to Claim 1 wherein the composition is a foam.

A¹⁵

13. A composition according to any of the preceding claims consisting substantially of:

sorbitan tristearate or non-ionic emulsifying wax 0.5 to 5% w/v

glycerol monostearate 0.5 to 5% w/v

light liquid paraffin 1 to 20% w/v

white soft paraffin 1 to 10% w/v

iso propyl myristate 0.5 to 5% w/v

polar drug 0.1 to 20% w/v

disodium edetate 0.01 to 1% w/v

amphoteric surfactant 0.1 to 10% w/v

alkoxyated cetyl alcohol 0.1 to 10% w/v

triclosan 0.01 to 1% w/v

benzyl alcohol 0.01 to 1% w/v

Sub 3

A15

cont. Sub B3
e. 10/10

purified water

to 100% of the emulsion

15. A method for treating a skin disease or condition, comprising:

(a) providing a polar drug selected from the group consisting of sodium cromoglycate and nedocromil sodium; and

(b) applying said polar drug to the skin of an individual affected by the disease or condition in or with a formulation comprising alkoxyated cetyl alcohol and an amphoteric surfactant.

17. A composition as in Claim 1 that is useful for treatment of a skin disease or condition by applying said composition to the skin of an individual affected by the disease or condition.

20. A method as in Claim 15 wherein the disease or condition is one in which skin mast cells and/or delayed hypersensitivity reactions and/or inflammation is thought to be involved.

21. A method as in Claim 15 in which the disease or condition is atopic dermatitis or eczema, contact sensitivity, psoriasis, drug sensitivity reactions, aphthous ulcers, Behcet's syndrome, pemphigus, urticaria, urticaria pigmentosa, pyoderma gangrenosum, chronic skin ulcers, ulcers associated with Crohn's disease, burns, insect